ADAPY:OTCMKTS
Adaptimmune Therapeutics PLC - ADR
US$ 0,0036
arrow_downward
-64,00%(-0,0064) 1D
1 de mai., 16:00:00 GMT-4 · USD
search
Todos os símbolos
1D
5D
1M
6M
YTD
1A
5A
MÁX
| Códigos | Preço | Variação | % de variação |
|---|
insights_autoGerando os principais insights para ADAPY…
Abrir
US$ 0,00
Alta
US$ 0,02
Baixa
US$ 0,00
Valor de mercado
954,19 mil
Volume médio
281,50 mil
Volume
64,61 mil
Alto — 52 sem
US$ 0,36
Baixo — 52 sem
US$ 0,00
LPA
-US$ 0,66
Beta
2,42
Ações em circulação
265,05 mi
Nº de funcionários
506
Notícias
De fontes em toda a Web
Financial Times
·
há 5 minutos
There is method in the market’s madness
MarketBeat
·
há 27 minutos
Clene Inc. (NASDAQ:CLNN) Given Average Rating of "Moderate Buy" by Analysts
Yahoo Finance
·
há 31 minutos
What Does Texas Instruments Incorporated's (NASDAQ:TXN) Share Price Indicate?
Perfil
Adaptimmune is a biopharmaceutical company that develops T cell therapies against cancer. The company was founded in 2008 in the UK with links to both Oxford University and the University of Pennsylvania. It has headquarters in Philadelphia and Milton Park.
In August 2024, the US Food and Drug Administration granted accelerated approval to Adaptimmune's Tecelra, a therapy against a rare form of cancer. Tecelra is the first T cell therapy to be approved for use against a solid tumor. In January 2025, the FDA granted breakthrough therapy designation to Adaptimmune's Letetresgene Autoleucel for Treatment of Myxoid/Round Cell Liposarcoma.
In July 2025, Adaptimmune announced their entry into a Definitive Agreement for Sale of Tecelra, lete-cel, and the pre-clinical uza-cel to US WorldMeds for $55M. Wikipedia
Sobre Adaptimmune Therapeutics PLC - ADR
O conteúdo gerado com IA pode ter erros. Saiba mais